195 related articles for article (PubMed ID: 33742733)
21. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
[TBL] [Abstract][Full Text] [Related]
22. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
[TBL] [Abstract][Full Text] [Related]
23. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients.
Romano LGR; Schütte LM; van Hest RM; Meijer K; Laros-van Gorkom BAP; Nieuwenhuizen L; Eikenboom J; Heubel-Moenen FCJI; Uitslager N; Coppens M; Fijnvandraat K; Driessens MHE; Polinder S; Cnossen MH; Leebeek FWG; Mathôt RAA; Kruip MJHA;
Haemophilia; 2024 Mar; 30(2):355-366. PubMed ID: 38343113
[TBL] [Abstract][Full Text] [Related]
24. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
McEneny-King A; Yeung CH; Edginton AN; Iorio A; Croteau SE
Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
[TBL] [Abstract][Full Text] [Related]
26. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
Arvanitakis A; Berntorp E; Astermark J
Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
[TBL] [Abstract][Full Text] [Related]
27. Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation.
Bukkems LH; Goedhart TMHJ; Zwaan CM; Cnossen MH; Mathôt RAA;
Blood Coagul Fibrinolysis; 2023 Apr; 34(3):171-178. PubMed ID: 37038844
[TBL] [Abstract][Full Text] [Related]
28. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
[TBL] [Abstract][Full Text] [Related]
29. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
[TBL] [Abstract][Full Text] [Related]
30. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A.
Björkman S
Haemophilia; 2010 Jul; 16(4):597-605. PubMed ID: 20148977
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
32. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
33. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
[TBL] [Abstract][Full Text] [Related]
34. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
[TBL] [Abstract][Full Text] [Related]
35. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A; Fischer K; Blanchette V; Rangarajan S; Young G; Morfini M;
Thromb Haemost; 2017 Jun; 117(6):1023-1030. PubMed ID: 28357444
[TBL] [Abstract][Full Text] [Related]
36. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
37. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
[TBL] [Abstract][Full Text] [Related]
38. Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
Allard Q; Djerada Z; Pouplard C; Repessé Y; Desprez D; Galinat H; Frotscher B; Berger C; Harroche A; Ryman A; Flaujac C; Chamouni P; Guillet B; Volot F; Szymezak J; Nguyen P; Cazaubon Y
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32326156
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model.
Zhu J; Wu YS; Beechinor RJ; Kemper R; Bukkems LH; Mathôt RAA; Cnossen MH; Gonzalez D; Chen SL; Key NS; Crona DJ
Haemophilia; 2021 Nov; 27(6):974-983. PubMed ID: 34405493
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.
Garmann D; McLeay S; Shah A; Vis P; Maas Enriquez M; Ploeger BA
Haemophilia; 2017 Jul; 23(4):528-537. PubMed ID: 28220555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
